Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field
Global agreement for oral anti-viral comes just months after company signed separate similar tie-up for a Covid mRNA vaccine also in development Key Takeaways Everest has signed a global licensing…
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
